Molecular Cancer Research Targeting the PI3-Kinase Pathway in Cancer Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strife, A.
Right arrow Articles by Clarkson, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strife, A.
Right arrow Articles by Clarkson, B.
Molecular Cancer Research 1:176-185 (2003)
© 2003 American Association for Cancer Research


Cancer Genes and Genomics

Direct Evidence That Bcr-Abl Tyrosine Kinase Activity Disrupts Normal Synergistic Interactions Between Kit Ligand and Cytokines in Primary Primitive Progenitor Cells1

Annabel Strife1, David Wisniewski1, Chongyuan Liu1, Caryl L. Lambek1, Zbigniew Darzynkiewicz4, Richard T. Silver3,5 and Bayard Clarkson1,2,3

1 Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute and 2 Department of Medicine, Memorial Hospital, Memorial-Sloan-Kettering Cancer Center, New York, NY;
3 Weill Medical College, Cornell University, New York, NY;
4 Cancer Research Institute, New York Medical College, Hawthorne, NY; and
5 New York-Presbyterian Cornell Medical Center, New York, NY

Requests for reprints: Bayard Clarkson, MSKCC Box 96—Room 401C-RRL, 430 East 67th Street, New York, NY 10021. Phones: (212) 639-7490 or 7491; Fax: (212) 717-3053. E-mail: b-clarkson{at}ski.mskcc.org; demerits{at}mskcc.org

We previously reported that chronic myelogenous leukemia (CML) primitive granulocyte-monocyte (GM) progenitors have a greatly reduced requirement for kit ligand (KL) to achieve optimal growth with granulocyte colony-stimulating factor (G-CSF) + granulocyte-monocyte colony-stimulating factor (GM-CSF). Conversely, others have demonstrated that unlike normal, CML CD34+ progenitors can proliferate in response to KL as a sole stimulus. To address these seemingly paradoxical findings, we examined the growth responses of CML CD34+ GM progenitors to various cytokines with and without a potent inhibitor of Bcr-Abl tyrosine kinase activity, PD173955. The heightened growth responses of CML GM progenitors to KL alone and to G-CSF + GM-CSF were abrogated by 10 nM PD173955 while having no effect on normal GM progenitors. While normal GM progenitors exhibited the expected synergistic response when KL was added to G-CSF + GM-CSF, CML GM progenitors had a minimal response; however, some synergism was restored by 10 nM PD173955. Normal erythroid progenitors require the synergistic interaction between KL and a saturating amount of erythropoietin (EPO, 1 unit) for optimal growth. In contrast, CML erythroid progenitors had up to 50% of optimal growth in KL alone, and, only a subthreshold amount of EPO (0.1 unit) was needed with KL to achieve 85% of the optimal response; these heightened growth responses were largely abrogated by 10 nM PD173955. Thus, direct evidence is provided that constitutively activated Bcr-Abl kinase pathways in primitive CML progenitors cooperate with single growth factors producing a heightened growth response, and, in so doing, disrupt the normally required synergistic interactions between KL and other cytokines to achieve activation and optimal growth of primitive progenitors. Coupled with our previous findings that a larger than normal proportion of CML primitive progenitors are at a later stage of maturation, we propose that this disruption of normal synergistic responses leads to increased progenitor recruitment into a committed pool by a process of accelerated maturation.




This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Holtz, S. J. Forman, and R. Bhatia
Growth Factor Stimulation Reduces Residual Quiescent Chronic Myelogenous Leukemia Progenitors Remaining after Imatinib Treatment
Cancer Res., February 1, 2007; 67(3): 1113 - 1120.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Liu and S. R. D'Mello
Phosphorylation of I{kappa}B-beta Is Necessary for Neuronal Survival
J. Biol. Chem., January 20, 2006; 281(3): 1506 - 1515.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. C. Fraering, W. Ye, M. J. LaVoie, B. L. Ostaszewski, D. J. Selkoe, and M. S. Wolfe
{gamma}-Secretase Substrate Selectivity Can Be Modulated Directly via Interaction with a Nucleotide-binding Site
J. Biol. Chem., December 23, 2005; 280(51): 41987 - 41996.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. E. Ouriaghli, E. Sloand, L. Mainwaring, H. Fujiwara, K. Keyvanfar, J. J. Melenhorst, K. Rezvani, G. Sconocchia, S. Solomon, N. Hensel, et al.
Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase
Blood, November 15, 2003; 102(10): 3786 - 3792.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
W. J. Netzer, F. Dou, D. Cai, D. Veach, S. Jean, Y. Li, W. G. Bornmann, B. Clarkson, H. Xu, and P. Greengard
Gleevec inhibits {beta}-amyloid production but not Notch cleavage
PNAS, October 14, 2003; 100(21): 12444 - 12449.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. von Bubnoff, D. R. Veach, W. T. Miller, W. Li, J. Sanger, C. Peschel, W. G. Bornmann, B. Clarkson, and J. Duyster
Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine-Type Small Molecule Kinase Inhibitors
Cancer Res., October 1, 2003; 63(19): 6395 - 6404.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.